Chemometec A/S Completes Share Buy‑Back Programme, Signals Confidence in Future Growth
On 2 October 2026, Chemometec A/S (ticker: CHEMOMETEC) announced the successful completion of its share buy‑back programme, a move that underscores the company’s commitment to enhancing shareholder value and reflects a renewed confidence in its strategic direction.
Strategic Context
Chemometec, headquartered in Allerød, Denmark, has built a robust portfolio of life‑sciences tools, including the NucleoCounter series of automated cell counters and the Xcyto quantitative cell imager. These instruments serve a broad spectrum of applications—from cell therapeutic and stem‑cell research to bioprocessing and toxicology—providing the company with a diversified revenue base.
The share buy‑back, executed through the Oslo‑Nordic market, aligns with Chemometec’s long‑term growth plan. By reducing the number of shares outstanding, the company aims to increase earnings per share, improve return on equity, and signal to investors that its current market price may undervalue the underlying business.
Market Reaction
Following the announcement, Chemometec’s shares settled at 519 DKK on 30 September 2026, a figure comfortably within the 52‑week range of 235.2 DKK to 804 DKK. The 45.08‑fold price‑to‑earnings ratio places the stock at a premium relative to many peers in the health‑care tools sector, suggesting that investors expect significant future earnings growth.
Short‑interest data from the Danish market, published by ProInvestor on 2 October 2026, indicates that Chemometec ranks 2.91 % among shorted stocks, a modest level that contrasts with higher short exposure seen in other listed companies such as Netcompany Group (8.99 %) and Carlsberg (5.37 %). This relatively low short‑interest implies that market participants are not overly skeptical of Chemometec’s prospects.
Growth Outlook
In a separate communiqué dated 1 October 2026, Chemometec’s management highlighted a “growth comeback” following a strategic reset. While the specific catalysts were not disclosed in the public brief, the timing of the buy‑back suggests that the company is confident in its ability to generate higher cash flows from its product lines and to invest in new research and development initiatives.
The company’s focus on cell‑counting and viability technologies positions it well to capture expanding demand in the global cell‑therapy and regenerative medicine markets. Moreover, Chemometec’s ancillary products—such as consumables, reagents, and software like NucleoView—provide recurring revenue streams that can help sustain profitability as the core instrument business scales.
Conclusion
Chemometec A/S’s completion of its share buy‑back programme, combined with a modest short‑interest profile and a management‑endorsed growth reset, paints a picture of a company that believes its current valuation does not fully reflect the value of its diversified product suite and its strategic trajectory. Investors observing the Nordic market will likely view this development as an affirmation of Chemometec’s ongoing commitment to shareholder value creation and to sustained innovation in the life‑sciences tools sector.
